8 Top Gainers In Healthcare Sector (LMAT, CLSD, LNTH...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. LeMaitre Vascular Inc. (LMAT)

LeMaitre Vascular is a provider of medical devices and implants for the treatment of peripheral vascular disease.

Gained 22.59% to close Wednesday's (Feb.20) trading at $30.77.

News: The Company announced better-than-expected fourth quarter and full-year 2018 financial results, and provided a rosy outlook for 2019.

Net income for the fourth quarter of 2018 jumped to $6.0 million or $0.30 per share on net sales of $28.4 million. Analysts polled by Thomson Reuters were expecting an EPS of $0.20 and revenue of $25.91 million. Net income was $4.28 million or $0.21 per share on net sales of $26 million in the fourth quarter of 2017.

For the first quarter of 2019, the Company expects EPS to range between $0.18 and $0.20, and sales to be in the range of $27.7 million to $28.5 million. Analysts have forecast consensus earnings of $0.20 per share and revenue of $27.18 million.

Looking ahead to the full year 2019, the Company expects EPS of $0.82 to $0.86 and sales of $113.0 million to $114.4 million while analysts expect earnings of 0.81 per share and revenue of $110.32 million.

LMAT was trading around $8 when we had alerted our premium subscribers to this stock in June 2014. (Report titled "It's All In the Name...").

2. Clearside Biomedical Inc. (CLSD)

Clearside Biomedical is a late-stage clinical biopharmaceutical company developing potential therapies to treat eye diseases.

Gained 20% to close Wednesday's trading at $1.74.

News: The Company's New Drug Application for XIPERE for Suprachoroidal Injection for the treatment of macular edema associated with uveitis has been accepted for review by the FDA - with a decision date set for October 19, 2019.

3. AzurRx BioPharma Inc. (AZRX)

AzurRx is a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases.

Gained 18.24% to close Wednesday's trading at $2.01.

News: The Company has dosed the first patient in its phase II study of MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency, dubbed OPTION.

The study is designed to enroll about 30 cystic fibrosis patients, with the results expected in mid-2019.

4. Axonics Modulation Technologies Inc. (AXNX)

Axonics Modulation is a medical technology company.

Gained 17.39% to close Wednesday's trading at $21.13. The stock was trading around $14 when it featured in our "In the Spotlight" column on January 7, 2019.

News: The Company announced positive top-line results from its ARTISAN-SNM pivotal study.

The ARTISAN-SNM study is evaluating the safety and efficacy of Axonics r-SNM System for urinary dysfunction. Axonics r-SNM System has secured marketing approvals in Europe, Canada, and Australia.

The clinical study demonstrated that patients implanted with the Axonics r-SNM System received clinically meaningful and statistically significant improvements in Urinary Urgency Incontinence ("UUI") symptoms and quality of life. Additionally, the study met all secondary endpoints.

5. Eyenovia Inc. (EYEN)

Eyenovia is a clinical stage, ophthalmic biopharmaceutical company.

Gained 15.44% to close Wednesday's trading at $4.86.

News: No news

Recent event:

-- On January 30, 2019, the Company announced that its phase III study evaluating MicroStat for pharmacologic mydriasis (eye dilation), dubbed MIST-1, met the primary endpoint.

The second phase III study in the MicroStat program for pharmacologic mydriasis, dubbed MIST-2 study, is underway, with results "expected to be announced in short order".

6. Lantheus Holdings Inc. (LNTH)

Lantheus manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases.

Gained 14.98% to close Wednesday's trading at $22.03.

News: The Company reported better-than-expected Q4 and full-year 2018 financial results.

Net income for the fourth quarter of 2018 declined to $13.29 million or $0.34 per share as revenue rose to $86.27 million. Analysts polled by Thomson Reuters were expecting an EPS of $0.14 and revenue of $83.72 million. Net income was $97 million or $2.47 per share and revenue was $81.24 million in the fourth quarter of 2017.

For the first quarter of 2019, the Company expects revenue in the range of $85 million to $87 million, and adjusted EPS in the range of $0.23 to $0.25. Analysts have forecast consensus earnings of $0.24 per share, and revenue of $88.52 million for Q1, 2019.

Looking ahead to full-year 2019, the Company expects revenue in the range of $358 million to $363 million, and adjusted EPS in the range of $1.14 to $1.17. Analysts have forecast consensus earnings of $0.96 per share, and revenue of $361.49 million for 2019.

7. Galectin Therapeutics Inc. (GALT)

Galectin Therapeutics is a clinical stage biopharmaceutical company developing therapies for fibrotic disease, skin disease, and cancer.

Gained 14.81% to close Wednesday's trading at $5.97.

News: No news

Pipeline:

The lead drug candidate is GR-MD-02 in NASH cirrhosis.

Clinical Trials & Near-term Catalysts:

The Company is proceeding with plans for a phase III trial GR-MD-02 in NASH Cirrhosis. Details of Phase 3 clinical trial design, including projected timings and costs, will be announced once the planning phase has been completed and the Company has submitted a final clinical trial protocol with the FDA.

8. Invitae Corporation (NVTA)

Invitae is a revenue-generating genetics company.

Gained 13.63% to close Wednesday's trading at $18.76.

News: The Company reported better-than-expected financial results for the fourth quarter and full year ended December 31, 2018.

Net loss for the fourth quarter of 2018 narrowed to $29.84 million or $0.40 per share on total revenue of $45.35 million. Analysts polled by Thomson Reuters were expecting a loss of $0.45 per share and total revenue of $40.78 million. Net loss was $40.49 million or $0.78 per share and total revenue was $25.39 million in the fourth quarter of 2017.